The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Developing biomarker-guided treatments for lung cancer
Luis Raez, MD, Memorial Cancer Institute, Pembroke Pines, FL, comments on updates on targeted therapies for lung cancer. Whilst some frequently seen mutations such as KRAS G12C have several treatment options, patients with p53 mutations do not have any available therapies. Lung cancer with STK11 and KEAP1 alterations additionally have promising immunotherapy-based strategies based on findings from the CheckMate 9LA (NCT03215706) and POSEIDON (NCT03164616) trials. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
